PREDIT
Our Proprietary AI-Powered Drug Discovery Platform
Central to Pharmaeconomica's innovative strategy is PREDIT, our proprietary AI-driven discovery platform. With custom machine learning algorithms designed specifically for targeted drug discovery, PREDIT enhances the precision and efficiency of identifying potential drug leads. This platform exemplifies the integration of AI technology in streamlining the pathway from molecular discovery to preclinical development, which could reduce the average cost of new drug discovery by approximately 40% and potentially shorten the drug development cycle.
Proprietary Algorithms
Our platform incorporates a suite of proprietary algorithms designed to enhance various stages of drug discovery:
​
-
Advanced Predictive Modeling: Utilizes deep learning and graph neural networks tailored for data represented in graphs to predict molecular interactions and drug efficacy.
-
Generative Design: Employs unique algorithms for drug structure generation, enabling the creation of novel compounds.
-
Optimized Molecular Modification: Uses reinforcement learning for adaptive techniques in improving molecule designs.
-
Low-Data Optimization: Features few-shot learning, transfer learning, and synthetic data generation to make the most of limited datasets.
-
Advanced Techniques for Sparse Data: Integrates active learning, Bayesian models, custom ensemble methods, and hybrid models to handle sparse data effectively.
-
Proprietary Frameworks for Explainable AI: Enhances transparency and understanding of AI decisions, ensuring regulatory compliance and trustworthiness.
Core Strengths and Capabilities
Pharmaeconomica’s expertise in artificial intelligence (AI) and computational chemistry is pivotal in our capacity to rapidly analyze complex biological data and identify potential therapeutic compounds. Our advanced peptide science enhances drug efficacy and stability, supported by an extensive in-house database of peptides, which includes non-canonical amino acids to optimize drug performance.
PREDIT, our proprietary platform, distinguishes itself by offering a tailored approach to drug discovery. This platform employs specialized machine learning algorithms to effectively target disease mechanisms, ensuring that only the most promising molecules progress further in development.
Your AI Partner in Drug Discovery
Pharmaeconomica's success highlights the game-changing power of AI in drug discovery, providing insights and methodologies that revolutionize research and development. These advancements showcase Pharmaeconomica's ability to deliver impactful results in crucial research areas, offering a valuable resource for R&D departments looking to leverage AI for similar successes. Our innovative work on Alzheimer’s disease, emerging viral infections and obesity marks significant steps toward future medical breakthroughs.
Highly Integrated Discovery Pipeline
Pharmaeconomica revolutionizes drug discovery by constructing precise protein structures without experimental data and employing refined proprietary algorithms and machine learning to distinguish active compounds from decoys. Our approach includes consensus docking and clustering to streamline ligand analysis, discovering promising chemical scaffolds with high affinity and selectivity for specific targets, and ensuring precise binding affinity predictions for both membrane-embedded and soluble protein-ligand complexes. We conduct MD simulations on top hits to evaluate their stability across diverse protein environments and utilize rigorous physics-based FEP calculations to accurately predict binding affinity for these top candidates. This innovative methodology optimizes drug candidates efficiently, advancing the future of medicine.
